Medical News

RSS

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.

19 Nov 2010

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that an interim analysis of all 86 patients enrolled in the company's Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.

19 Nov 2010

Scientists discover bone matrix plays a vital role in tissue hardening

Scientists are reporting the first direct evidence that a subtle change in the physical properties of a tissue can affect its function. The finding has immediate implications for understanding several rare hearing disorders, they said, and ultimately could offer insight into such conditions as osteoporosis, arthritis, cardiovascular disease and cancer.

19 Nov 2010

St. Jude Medical completes acquisition of AGA Medical

St. Jude Medical, Inc. today announced that it has successfully completed its acquisition of AGA Medical Holdings, Inc.

19 Nov 2010

Bristol-Myers Squibb prices cash tender offer for $750 million

Bristol-Myers Squibb Company announced today the pricing terms of its previously announced cash tender offer for up to $750 million aggregate principal amount of certain of its outstanding debt securities.

19 Nov 2010

Study finds adverse long term health effects of E coli infection

People who contract gastroenteritis from drinking water contaminated with E coli are at an increased risk of developing high blood pressure, kidney problems and heart disease in later life, finds a study published online in the British Medical Journal.

19 Nov 2010

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Ipsen announced today that its partner Inspiration Biopharmaceuticals, Inc. has initiated treatment of patients in the first of two phase III pivotal clinical studies of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder.

19 Nov 2010

Medtronic launches Tri-Ad ring for tricuspid valve disease

Medtronic, Inc. today announced the global launch and first clinical use of the Tri-Ad Semi-Flexible Tricuspid Annuloplasty Ring for the treatment of tricuspid valve disease.

19 Nov 2010

KHN column -- the Texas Medicaid scenario: Why it's never going to happen

When I first heard about this controversy, I noted one simple fact that deserves greater play: This is not going to happen. Withdrawing from Medicaid would be political suicide.

19 Nov 2010

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced four key belinostat data presentations at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

19 Nov 2010

HSR Act applicable to LabCorp’s acquisition of Genzyme

Laboratory Corporation of America Holdings today announced that it has received early termination from the Federal Trade Commission of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Genzyme Genetics, a business unit of Genzyme Corp. by LabCorp.

19 Nov 2010

Sec. of State Clinton begins discussing QDDR draft with U.S. lawmakers

Secretary of State Hillary Rodham Clinton began rolling out her long-awaited revamp of U.S. diplomatic strategy on Wednesday, meeting lawmakers to discuss the 'Quadrennial Diplomacy and Development Review' (QDDR) that is expected to be formally announced later this year, Reuters reports.

19 Nov 2010

Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced positive top-line results of the APEX-PD Phase III clinical study with IPX066 in Parkinson's disease (PD). IPX066 is a novel extended release carbidopa-levodopa product.

19 Nov 2010

Ethicon submits BLA to FDA for Fibrin Pad

Ethicon, Inc., a worldwide leader in surgical care, announced today that the company has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the Fibrin Pad, a novel product candidate that combines Ethicon's biomaterials and plasma-derived biologics (Human Fibrinogen and Human Thrombin), to aid in stopping soft tissue bleeding during surgery.

19 Nov 2010

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

19 Nov 2010

Cardinal Health announces plan to acquire Kinray

Cardinal Health today announced plans to acquire Kinray, Inc., a leading pharmaceutical distributor serving the New York metropolitan area, for $1.3 billion in an all-cash transaction that will significantly expand its ability to serve retail independent pharmacies in the northeastern United States.

19 Nov 2010

Berwick's first hearing marked by strong defense of health law, GOP 'relative gentleness'

Centers for Medicare and Medicaid Services chief Dr. Donald Berwick survived his first Senate hearing yesterday by rebutting criticism of the health law and because Republicans were relatively gentle, The New York Times reports.

19 Nov 2010

Sekisui enters asset purchase agreement to acquire Genzyme's Diagnostic products

Genzyme Corporation today announced that it has entered into an asset purchase agreement under which Sekisui Chemical Co., Ltd. will acquire Genzyme's Diagnostic products business for $265 million in cash.

19 Nov 2010

Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that the Company's senior executives presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, ongoing in Berlin, Germany.

19 Nov 2010

FDA approves IDE application for Home Hemodialysis system

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application for a Home Hemodialysis (HD) system in development through a collaboration between DEKA Research and Development Corp., HHD LLC, and Baxter.

From Baxter International Inc. 19 Nov 2010

Medical News

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Scientists discover bone matrix plays a vital role in tissue hardening

St. Jude Medical completes acquisition of AGA Medical

Bristol-Myers Squibb prices cash tender offer for $750 million

Study finds adverse long term health effects of E coli infection

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Medtronic launches Tri-Ad ring for tricuspid valve disease

KHN column -- the Texas Medicaid scenario: Why it's never going to happen

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

HSR Act applicable to LabCorp’s acquisition of Genzyme

Sec. of State Clinton begins discussing QDDR draft with U.S. lawmakers

Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease

Ethicon submits BLA to FDA for Fibrin Pad

Elorac announces results of Phase III CPO solution studies for acne at Healthcare Conference in New York

Cardinal Health announces plan to acquire Kinray

Berwick's first hearing marked by strong defense of health law, GOP 'relative gentleness'

Sekisui enters asset purchase agreement to acquire Genzyme's Diagnostic products

Cerulean presents data on CRLX101, CRLX288 study for cancer at EORTC-NCI-AACR Symposium

FDA approves IDE application for Home Hemodialysis system

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News